Intuitive Surgical
Intuitive Surgical, Inc.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$10.1B
Operating marginCalculated
29.3%
Net assets to total assetsCalculated
87.1%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★★position among all companies
29.3%
Growth (revenue, 4-year average)
★★★★★position among all companies
15.2%
Capital efficiency
★★★★☆position among all companies
16.0%
Revenue and profit
Performance, financial position and capital allocation
Intuitive Surgical
Recent performance trends
Intuitive Surgical
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$5.7 billion | US$6.2 billion | US$7.1 billion | US$8.4 billion | US$10.1 billion |
| Operating income | US$1.8 billion | US$1.6 billion | US$1.8 billion | US$2.3 billion | US$2.9 billion |
| Net income | US$1.7 billion | US$1.3 billion | US$1.8 billion | US$2.3 billion | US$2.9 billion |
| Total assets | US$13.6 billion | US$13.0 billion | US$15.4 billion | US$18.7 billion | US$20.5 billion |
| Shareholders' equity | US$11.9 billion | US$11.0 billion | US$13.3 billion | US$16.4 billion | US$17.8 billion |
| Net cash provided by (used in) operating activities | US$2.1 billion | US$1.5 billion | US$1.8 billion | US$2.4 billion | US$3.0 billion |
| Net cash provided by (used in) investing activities | US$-2.5 billion | US$1.4 billion | US$-0.4 billion | US$-3.3 billion | US$0.7 billion |
| Net cash provided by (used in) financing activities | US$43.00 million | US$-2.6 billion | US$-0.3 billion | US$0.2 billion | US$-2.4 billion |
| Cash and cash equivalents | US$1.3 billion | US$1.6 billion | US$2.8 billion | US$2.0 billion | US$3.4 billion |
Revenue scale in the same industry
Intuitive Surgical
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 8 companies
- 12 KLAFY Jun 2026 US$13.6B
- 13 Baxter InternationalFY Dec 2025 US$11.2B
- 14 Intuitive SurgicalThis companyFY Dec 2025 US$10.1B
- 15 Rockwell AutomationFY Sep 2025 US$8.3B
- 16 SolventumFY Dec 2025 US$8.3B
- … 27 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.5 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$3.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-2.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$0.7 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$3.0 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.6 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$17.9 billion | Consolidated | Disclosed |
| Non-controlling interests | US$0.1 billion | Consolidated | Disclosed |
| Net assets | US$17.8 billion | Consolidated | Disclosed |
| Net sales | US$10.1 billion | Consolidated | Disclosed |
| Operating income | US$2.9 billion | Consolidated | Disclosed |
| Net income | US$2.9 billion | Consolidated | Disclosed |
| Total assets | US$20.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$2.3 billion | Consolidated | Disclosed |
| Operating margin | 29.3% | Consolidated | Calculated |
| Net assets to total assets | 87.1% | Consolidated | Calculated |
| Net margin | 28.4% | Consolidated | Calculated |
| Return on equity | 16.0% | Consolidated | Calculated |